India’s pharmaceutical industry is the third largest globally by volume, and the growth drivers remain strong going into 2026. Rising health insurance coverage, an ageing population, and steady demand for generic drug exports are supporting long-term expansion. At the same time, better healthcare awareness and improving hospital infrastructure are increasing domestic demand.
For investors, pharma sector mutual fund offers access in this growth without having to pick individual stocks. These funds are managed by professionals who track regulatory changes, company performance, and sector trends closely.
In this guide, we break down the best pharma mutual funds, who should consider them, key risks, taxation, and how to get started.
Key Takeaways
- Pharma and healthcare mutual funds focus on companies across pharmaceuticals, hospitals, diagnostics, and biotech
- The best pharma mutual funds can deliver strong returns over a 5–7 year horizon, but come with higher volatility
- SIP investing helps manage risk and smooth out market cycles
- Always compare expense ratio, portfolio concentration, and fund manager track record before investing
What Are Pharma Mutual Funds?
Pharma mutual funds are sectoral funds that invest primarily in companies from the pharmaceutical and broader healthcare space. Instead of choosing individual stocks, your money is managed by professionals who track industry trends, regulatory updates, and company performance.
How Pharma Sector Mutual Funds Work
Pharma funds pool money from multiple investors and invest it across healthcare-related companies. Most pharma sector mutual funds allocate at least 80% of their portfolio to this space.
You’ll typically see a mix of:
- Large pharma companies with stable revenues
- Mid-cap players with higher growth potential
- Select exposure to healthcare services and tech
Pharma Funds vs. Healthcare Funds — What’s the Difference?
The key difference comes down to how broad the fund’s exposure is.
- Pharma funds invest only in pharmaceutical companies
- Healthcare mutual funds go wider; including hospitals, diagnostics, biotech, and healthcare platforms
Top 7 Best Pharma Mutual Funds in India (2026)
Pharma and healthcare mutual funds have seen strong traction as the sector continues to grow steadily in India. Over the past few years, many of these funds have delivered solid 3-year returns in the 20–28% range.
That said, these are sectoral funds, which means higher volatility. It’s best to keep allocation within 10–15% of your overall portfolio.
| Fund Name | AUM (₹ Cr) | 3-Yr CAGR | Min SIP (₹) | Best For |
| Nippon India Pharma Fund | 8,357 | 22% | 100 | Long-term growth seekers |
| ICICI Pru Pharma Healthcare & Diagnostics Fund | 6,801 | 28% | 100 | High-return focused investors |
| SBI Healthcare Opportunities Fund | 4,077 | 26% | 500 | Balanced exposure |
| UTI Healthcare Fund | 1,097 | 25% | 500 | Consistent performers |
| DSP Healthcare Fund | 3,107 | 24% | 3,000 | Diversified healthcare exposure |
| Mirae Asset Healthcare Fund | 2,796 | 22–23% | 3,000 | Emerging opportunities |
| Tata India Pharma & Healthcare Fund | 1,296 | 23% | 100 | Value-focused investors |
Key Metrics to Compare Before You Invest
Before choosing the best pharma mutual funds, focus on these:
- Expense ratio: Direct plans typically range between 0.3–0.8%, while regular plans can go up to 2.5%. Lower costs help improve long-term returns.
- Standard deviation (volatility): The category average is around 13%. Funds below this tend to fluctuate less.
- Portfolio concentration: Some funds allocate heavily to a few stocks or only pharma companies. Check top holdings to avoid over-concentration.
- Fund manager track record: Look at the manager’s experience in handling sector funds and how consistently they’ve beaten the benchmark (like the BSE Healthcare Index).
Who Should Invest in Pharma Sector Mutual Funds?
Pharma and healthcare mutual funds can add strong growth potential to a portfolio, but they are not meant for everyone. The key is knowing whether they fit your time horizon and risk comfort.
Ideal Investor Profile
- You believe in the long-term growth of the healthcare and pharma sector
- You’re comfortable with moderate ups and downs in returns
- You have an investment horizon of at least 5–7 years
- You already have a core portfolio (large-cap or flexi-cap funds) in place
- You’re looking to allocate a small portion for higher return potential
Who Should Avoid Pharma Mutual Funds?
- You’re a first-time investor relying on a single fund for your entire portfolio
- You need stability and cannot handle short-term volatility
- Your investment horizon is less than 3 years
- You’re looking for predictable or fixed-like returns
Key Risks of Investing in Best Healthcare Mutual Funds
Pharma and healthcare funds can deliver strong returns, but they come with specific risks that investors should be aware of before allocating money.
4 Risks Every Pharma Fund Investor Must Know
- Sector concentration risk: These funds invest only within healthcare. If the sector underperforms, your entire allocation is affected.
- Regulatory risk: Pharma companies are closely regulated. Events like US FDA warnings or plant issues can impact stock prices and, in turn, fund performance.
- Currency risk: Many Indian pharma companies earn from exports. A stronger rupee can reduce margins and affect earnings.
- Underperformance cycles: Even though pharma is seen as a relatively stable sector, it goes through phases of weak returns. Short-term performance can be uneven.
How to manage this: Keep exposure limited to 10–15% of your portfolio and balance it with a large-cap or flexi-cap fund as your core holding.
Tax Rules for Pharma Mutual Funds in India (2026)
Pharma and healthcare mutual funds are treated as equity funds since they invest more than 80% in stocks. So, standard equity taxation applies:
- Short-term capital gains (STCG): If held for less than 12 months, gains are taxed at 20%
- Long-term capital gains (LTCG): If held for more than 12 months, gains above ₹1.25 lakh in a financial year are taxed at 12.5%
- Dividend income: Added to your total income and taxed as per your slab
What to keep in mind: Holding your investment for over a year can reduce your tax outgo. SIPs work well here, as they spread investments over time and support a longer holding approach.
Conclusion
India’s pharma and healthcare sector continues to show steady long-term potential, backed by exports, domestic demand, and policy support. Funds like ICICI Pru Pharma Healthcare & Diagnostics (28%), SBI Healthcare Opportunities (26%), and UTI Healthcare Fund (25%) have delivered strong 3-year performance.
Limit exposure to 10–15% of your portfolio and pair it with a flexi-cap or large-cap fund for balance. Consult a SEBI-registered financial advisor before investing.
FAQ on Pharma Mutual Funds
The sector is currently viewed as being in a “recovery phase” with reasonable valuations and strong domestic demand, making it a potentially good time for long-term entry. However, as a sectoral play, it is best suited for investors with a high risk appetite who can stay invested through 5+ year cycles.
The minimum SIP amount is very accessible, starting at ₹100 for funds like Nippon India Pharma and ICICI Prudential P.H.D. Most other schemes in this category, such as SBI Healthcare Opportunities, typically require a minimum of ₹500 per month.
Pharma is considered a “defensive” sector because the demand for medicine remains stable regardless of economic downturns. However, they are not “safe” in the absolute sense; they carry high concentration risk and can be volatile due to USFDA regulatory actions or government pricing controls.
Pharma is considered a “defensive” sector because the demand for medicine remains stable regardless of economic downturns. However, they are not “safe” in the absolute sense; they carry high concentration risk and can be volatile due to USFDA regulatory actions or government pricing controls.
Pharma funds focus primarily on drug manufacturing and research, while healthcare funds have a broader mandate. Healthcare funds invest across the entire ecosystem, including hospitals, diagnostic chains, medical equipment, and pharmacies, providing slightly better internal diversification.
As equity-oriented funds, Short-Term Capital Gains (STCG) on holdings under 12 months are taxed at 20%. Long-Term Capital Gains (LTCG) for holdings over 12 months are taxed at 12.5% on gains exceeding ₹1.25 lakh in a financial year.
Disclaimer: Investments in securities markets are subject to market risks. Read all the related documents carefully before investing. The securities quoted are exemplary and are not recommended.
